Published within
|«
«
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
...
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
Wyeth has discontinued a phase III trial of temsirolimus plus letrozole in metastatic post-menopausal hormone-receptor positive breast cancer. This is a significant blow for the company due to the loss of earnings potential in the congested but lucrative breast cancer market. However, temsirolimus remains under development for a number of other tumors, and so hope for the drug candidate remains.
Published By Datamonitor
|
23 Mar 2006 |
|
CommentWire
|
The current economic environment has paved the way for leading pharmaceutical firms to sweep in and buy up smaller players, highlighted by Wyeth's potential acquisition of Crucell and Merck & Co's strategy to aggressively look for targets in 2009. An increasing number of pharmaceutical majors are likely to use this approach to strengthen their biologic portfolios and access novel pipeline drugs.
Published By Datamonitor
|
09 Jan 2009 |
|
CommentWire
|
Following poor first-year performance, Wyeth [WYE] and MedImmune [MEDI] have announced the dissolution of their FluMist partnership. If MedImmune is to achieve success with this product alone, it may need to rethink its premium pricing strategy.
Published By Datamonitor
|
28 Apr 2004 |
|
CommentWire
|
Wyeth [WYE] and MedImmune's [MEDI] FluMist failed to secure indications for use in key target groups for influenza vaccine in the US. Recently released results suggest that their second generation product may enable the two companies to capitalize on more conventional influenza vaccine sectors.
Published By Datamonitor
|
15 Oct 2003 |
|
Expert View
|
Datamonitor attended this year's International Osteoporosis Foundation World Congress on Osteoporosis and 10th European Congress on Clinical and Economical Aspects of Osteoporosis and Osteoarthritis, the most important meeting on the osteoporosis calendar. A number of major pharmaceutical firms had a presence at the meeting, indicating the significance of this market.
Published By Datamonitor
|
18 May 2010 |
|
CommentWire
|
While the drug is undeniably highly effective at treating breast cancer, some of the efforts to use it as a preventative medicine may be more questionable. For many women, the side effects could prove more dangerous than the risk of breast cancer. More studies need to be carried out to determine exactly which groups will benefit from the drug.
Published By Datamonitor
|
05 Nov 2001 |
|
CommentWire
|
Chlamydia is the US' most prevalent bacterial STD, and can cause infertility if untreated. The new guidelines should boost the use of non-culture tests from companies such as BD Diagnostics, which are cheap and can be performed by primary care physicians.
Published By Datamonitor
|
14 May 2002 |
|
CommentWire
|
Cardiovascular disease is the US' biggest killer of women - but too many believe that diseases such as breast cancer are a greater threat. The new initiative should be a major step in combating the disease through educating and changing behavior. This should benefit both at-risk patients and pharma companies active in the female-specific CVD market.
Published By Datamonitor
|
04 Feb 2002 |
|
Expert View
|
One in 10 cancer patients fall foul of brain metastases - a patient population as large as that of lung or breast cancer. Despite this demand - and although many drugs have been shown to have activity in brain metastases - none are commonly used. This leaves a market with great unmet need and little competition - but who will fill the hole?
Published By Datamonitor
|
01 Feb 2002 |
|
CommentWire
|
Watson Pharmaceuticals's Gelnique is the first gel to be approved by the FDA for the treatment of overactive bladder, and provides an advantageous side-effect profile over current oral anticholinergic and patch treatments. As a result, Datamonitor expects Gelnique to be beneficial for a niche population and to generate $124m in 2016.
Published By Datamonitor
|
28 Jan 2009 |
|
|«
«
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
...
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.